Tectonic Therapeutic, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for pulmonary hypertension and related cardiovascular diseases. The company's lead candidate, TX45, is advancing through a pivotal Phase 2 APEX trial with data expected in 2026. Financial results reveal widening net losses driven by increased R&D expenses, with FY2025 net loss of $74.15 million and operating loss of $84.04 million, reflecting deeper investment in clinical programs [F1]. Despite ongoing cash burn, the company maintains a strong liquidity position with cash and equivalents of $253.8 million and a current ratio above 26x at year-end 2025, providing a solid runway for continued development. Capital allocation prioritizes pipeline advancement without dividends or share repurchases reported [S21][S22][S23]. Governance enhancements include board expansion and appointment of an independent Chair to oversee strategic execution and risk management [S21][S22][S23].